Anzeige
Mehr »
Mittwoch, 07.01.2026 - Börsentäglich über 12.000 News
Wie ein junger Batterie-Spezialist plötzlich zum unverzichtbaren Partner wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
10.11.25AI-driven Iambic raises $100M-plus as it looks to advance pipeline, strike more deals
10.11.25Cogent eyes FDA submission for cancer asset after clearing another phase 3 hurdle
10.11.25Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts
10.11.25AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail
10.11.25Lyell hands over $70M-plus in cash, equity for 'impressive' phase 1-stage colorectal cancer CAR-T
10.11.25Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed
10.11.25AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win
10.11.25FDA puts Tenaya heart disease gene therapy clinical trial on hold
10.11.25Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds
08.11.25Pfizer beats out Novo with $10B agreement to buy Metsera
07.11.25Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates
07.11.25Patient dies after receiving Intellia's CRISPR therapy
06.11.25FDA reveals second round of 'national priority' voucher winners, including obesity giants Lilly and Novo
06.11.25Cullinan sidelines pair of oncology assets amid expansion into autoimmune R&D
06.11.25Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition
06.11.25UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data
06.11.25Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3
06.11.25Moderna's phase 3 norovirus study heads north again after struggling to find cases down south
06.11.25Inflammation biotech Evommune heads to NYSE with $150M IPO
06.11.25AstraZeneca drops MASH drug over disappointing phase 2 data
06.11.25Dynavax pays Vaxart $30M for oral COVID-19 vaccine program
05.11.25FTC warns Novo that current Metsera offer structure may violate US merger law
05.11.25Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&D shake-up
05.11.25Lilly pulls out of CNS portion of $960M RIPK1 inhibitor collab with Rigel
05.11.25Novo Nordisk CEO 'feels' Danish pharma will bag Metsera at end of Pfizer bidding war